Titterton Lewis H jr purchased $132K of ANIX

Titterton Lewis H jr purchased 49,036 shares of Anixa Biosciences Inc (ANIX) at $2.69 ($0.13M total) on 2026-09-23.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Sep 25, 2026, 12:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The filing provides the first public disclosure of this insider purchase, offering a fresh data point for traders.

02

Market read

Direct insider buying may influence short‑term trading decisions for ANIX.

03

What to watch

The purchase amount is small; larger institutional activity would be more material.

Relevance 5/10Novelty 4/10Timing: post‑market filing on 2026‑09‑23

Background

Form 4 filings disclose insider transactions; director purchases are monitored for potential signals.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

Director Titterton Lewis H Jr bought 49,036 shares for $131,907, increasing his stake to over 1 million shares.

Expected impact

Modest upward pressure as market may view the purchase favorably.

Evidence & confidence

The purchase size is modest relative to market cap, but director involvement adds credibility.

Market effects

May slightly boost sentiment in the biotech sector as insider buying is viewed positively.

Limited to U.S. markets where ANIX trades.

Minimal global impact.

Counterpoint

Insider purchase could be routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Anixa Biosciences Inc

    Biotech firm listed on NASDAQ under ticker ANIX.

  • Titterton Lewis H Jr

    Director of Anixa Biosciences who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXLowAI 8/10

Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.